Eli Lilly and Co (LLY)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Eli Lilly and Co (LLY) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011710
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:113
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eli Lilly and Company (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, critical care, men’s health and musculoskeletal problems. It also provides pet medicine, food-safety products and companion animal health products, besides services to the food animal industry. Lilly also has mid-to-late stage pipeline portfolio for conditions such as diabetes, cancer, neurological problems and autoimmune disorders. The company distributes human pharmaceutical and animal health products through independent wholesale distributors. It also promotes its products through sales representatives and marketing agreements with other pharmaceutical companies. The company offers its products in the US, Europe, Japan and Other foreign countries. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co (LLY) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Eli Lilly and Co, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Eli Lilly and Co, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Eli Lilly and Co, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Eli Lilly and Co, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Eli Lilly and Co, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Eli Lilly and Co, Medical Equipment, Deal Details 12
Asset Purchase 12
Eli Lilly Acquires Two Alzheimer’s Disease Imaging Agents From Siemens Medical Solutions 12
Venture Financing 14
Veritas Genetics Raises USD30 Million in Series B Financing 14
Millin Enterprises Raises Funds through Series A financing 15
ACEA Biosciences Raises USD30 Million in Venture Financing 16
Microtech Medical Raises Funds through Series A Financing 17
Veritas Genetics Raises USD10 Million in Series A Financing Round 18
Companion Medical Raises USD3.15 Million in Series B Financing 19
Partnerships 20
DexCom Enters into Agreement with Eli Lilly 20
Insulet Enters into Co-Development Agreement with Eli Lilly 21
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 22
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 23
Exosome Diagnostics Enters Into Agreement With Eli Lilly To Discover Biomarker 24
Corgenix Enters Into Co-Development Agreement With Eli Lilly 25
Insulet Enters Into Co-Development Agreement With Eli Lilly 26
Qiagen Enters Into Co-Development Agreement With Eli Lilly 27
Dako Enters Into Agreement With Eli Lilly To Develop Companion Diagnostic Tests 28
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 29
Cardinal Health Enters Into Co-Marketing Agreement With Eli Lilly For Amyvid 30
PETNET Solutions Enters Into Distribution Agreement With Eli Lilly and Company 31
QIAGEN Enters Into Co-Development Agreement With Eli Lilly 32
Synthes Enters Into Co-Development Agreement With Eli Lilly 33
Eli Lilly Enters Into Collaboration With Medtronic 34
Equity Offering 35
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 35
Eli Lilly and Co – Key Competitors 37
Eli Lilly and Co – Key Employees 38
Eli Lilly and Co – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Joint Venture 47
Recent Developments 49
Strategy And Business Planning 49
Sep 07, 2017: Lilly Takes Steps To Streamline Business, Invest In New Medicines And Drive Growth 49
Financial Announcements 50
Oct 24, 2017: Lilly Reports Third-Quarter Results 2017 50
Jul 25, 2017: Lilly Reports Second-Quarter Results 55
Apr 25, 2017: Lilly Reports First-Quarter 2017 Results 59
Jan 31, 2017: Lilly Reports Fourth-Quarter And Full-Year 2016 Results 63
Dec 15, 2016: Lilly Provides 2017 Financial Guidance And 2016 Update, Reaffirms Financial Expectations Through The Remainder Of The Decade 69
Oct 25, 2016: Lilly Reports Third-Quarter 2016 Results 71
Jul 26, 2016: Lilly Reports Second-Quarter 2016 Results, Provides Financial Expectations Through The Remainder Of The Decade 75
Apr 26, 2016: Lilly Reports First-Quarter 2016 Results, Revises 2016 Financial Guidance 79
Jan 28, 2016: Lilly Reports Fourth-Quarter And Full-Year 2015 Results 83
Corporate Communications 89
Dec 11, 2017: Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology 89
Nov 13, 2017: Lilly Appoints Philip Johnson to Senior Vice President and Treasurer 90
Sep 29, 2017: Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing 91
Jun 01, 2017: Derica Rice To Retire As Lilly Chief Financial Officer 92
May 10, 2017: Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications 93
Mar 02, 2017: Lilly Announces Changes In Senior Management 94
Feb 09, 2017: Carolyn R. Bertozzi, Ph.D., Elected To Lilly Board Of Directors 95
Sep 14, 2016: Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career 96
Aug 31, 2016: Jamere Jackson Elected To Lilly Board Of Directors 97
Aug 10, 2016: Lilly announces Joshua Smiley, Anat Ashkenazi appointed to new roles, Thomas Grein retires 98
Jul 27, 2016: John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor 99
Jun 13, 2016: Aarti Shah named chief information officer 101
Government and Public Interest 102
Apr 04, 2017: Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students 102
Product News 103
Jul 27, 2016: New Studies Suggest Relationship Between Tau Pathology And Progression Of Alzheimer’s Disease 103
Other Significant Developments 105
Sep 25, 2017: Geisinger And Boehringer Ingelheim Collaborate To Create A Predictive Model To Help Improve Health Outcomes For People With Type 2 Diabetes 105
Jun 21, 2017: Eli Lilly And Company Unveils Expanded Biotechnology Center In San Diego 106
May 17, 2017: Cogstate Selected as Preferred Provider to Lilly’s Alzheimer’s Disease Platform 107
Jan 05, 2017: Lilly To Adjust Organization And Leadership Structure To Better Align With Growth Opportunities 108
Oct 17, 2016: Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative 109
Jun 17, 2016: Lilly Launches Domestic Production of Entire Range of Humulin, Humalog Insulins and Long Acting Insulin Analogue in partnership with R-Pharm Group 110
May 24, 2016: Lilly Details Robust R&D Pipeline to Investment Community 111
Feb 24, 2016: Indiana Biosciences Research Institute Announces $100 Million in Grants Supporting Scientific Innovation to Address Metabolic Disease and Poor Nutrition 112
Appendix 113
Methodology 113
About GlobalData 113
Contact Us 113
Disclaimer 113

List of Tables
Eli Lilly and Co, Medical Equipment, Key Facts, 2016 2
Eli Lilly and Co, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Eli Lilly and Co, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Eli Lilly and Co, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Eli Lilly and Co, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Eli Lilly and Co, Deals By Market, 2011 to YTD 2017 9
Eli Lilly and Co, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Eli Lilly Acquires Two Alzheimer's Disease Imaging Agents From Siemens Medical Solutions 12
Veritas Genetics Raises USD30 Million in Series B Financing 14
Millin Enterprises Raises Funds through Series A financing 15
ACEA Biosciences Raises USD30 Million in Venture Financing 16
Microtech Medical Raises Funds through Series A Financing 17
Veritas Genetics Raises USD10 Million in Series A Financing Round 18
Companion Medical Raises USD3.15 Million in Series B Financing 19
DexCom Enters into Agreement with Eli Lilly 20
Insulet Enters into Co-Development Agreement with Eli Lilly 21
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 22
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 23
Exosome Diagnostics Enters Into Agreement With Eli Lilly To Discover Biomarker 24
Corgenix Enters Into Co-Development Agreement With Eli Lilly 25
Insulet Enters Into Co-Development Agreement With Eli Lilly 26
Qiagen Enters Into Co-Development Agreement With Eli Lilly 27
Dako Enters Into Agreement With Eli Lilly To Develop Companion Diagnostic Tests 28
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 29
Cardinal Health Enters Into Co-Marketing Agreement With Eli Lilly For Amyvid 30
PETNET Solutions Enters Into Distribution Agreement With Eli Lilly and Company 31
QIAGEN Enters Into Co-Development Agreement With Eli Lilly 32
Synthes Enters Into Co-Development Agreement With Eli Lilly 33
Eli Lilly Enters Into Collaboration With Medtronic 34
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 35
Eli Lilly and Co, Key Competitors 37
Eli Lilly and Co, Key Employees 38
Eli Lilly and Co, Subsidiaries 40
Eli Lilly and Co, Joint Venture 47

★海外企業調査レポート[Eli Lilly and Co (LLY)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lupin Pharmaceuticals, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Lupin Pharmaceuticals, Inc. Mer …
  • Public Power Corporation S.A. (PPC):企業のM&A・提携動向(エネルギー分野)
    Summary Public Power Corporation S.A. (PPC) is an energy company. The company designs, constructs, maintains and operates power plants. It generates, transmits and distributes electricity. The company generates power from lignite, fuel oil, and natural gas based plants. It also generates power from …
  • Viridian Energy Supply Ltd.-エネルギー分野:企業M&A・提携分析
    Summary Viridian Energy Supply Ltd. (trading as Energia) a subsidiary of Viridian Group Investments Limited, is a vertically integrated energy company that supplies electricity and gas; and provides energy efficiency services. It provides energy to micro, small and medium-sized enterprises, and resi …
  • Hermes International SA:企業の戦略・SWOT・財務分析
    Hermes International SA - Strategy, SWOT and Corporate Finance Report Summary Hermes International SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Qatar Petroleum:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Qatar Petroleum Mergers and Acq …
  • Kaefer Isoliertechnik GmbH & Co KG:企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Kaefer Isoliertechnik GmbH & Co KG" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric …
  • Australian Oil Company Limited (AOC):企業の財務及び戦略的SWOT分析
    Summary Australian Oil Company Limited (AOC) is an oil and gas company that offers exploration services. The company concentrates on exploration of oil and gas properties in Australia and overseas. Its project areas comprise of California, Coalinga, Porters Ranch, Manikins Ranch, EP 435 Carnarvon ba …
  • Motorola Mobility, Inc.:企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Motorola Mobility, Inc." The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly f …
  • LG Corp.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' LG Corp. Mergers and Acquisitio …
  • Union Insurance Co., Ltd.:企業の戦略・SWOT・財務分析
    SummaryUnion Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. K …
  • Sinovac Biotech Ltd.(製薬・医療分野):企業M&A動向
    Summary Sinovac Biotech Ltd (Sinovac Biotech) is a biopharmaceutical company. The company researches, develops, manufactures and commercializes vaccines that protect against human infectious diseases. Its products include Healive, an inactivated hepatitis A vaccine, Bilive, a combined inactivated he …
  • Euro-Diagnostica AB:企業のM&A・提携動向(医療機器分野)
    Summary Euro Diagnostica AB (Euro-Diagnostica) is a medical diagnostic company that provides full service clinical diagnostic solutions. The company offers blood based solutions, developed to aid clinicians in diagnosis, prognosis, monitoring and treatment of autoimmune diseases. Its products find u …
  • Adagio Pharmaceuticals, Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Adagio Pharmaceuticals, Ltd. Me …
  • MaxSec Group Limited:企業の戦略・SWOT・財務分析
    SummaryMaxSec Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Fi …
  • Etisalat DB Telecom Pvt., Ltd. (formerly Swan Telecom Pvt., Ltd.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Etisalat DB Telecom Pvt., Ltd. …
  • Alkane Energy Plc (ALK):企業の財務及び戦略的SWOT分析
    Summary Alkane Energy Plc (Alkane Energy) is a power company that generates electricity. The company designs, builds, and operates coal mine methane sites. It produces power from coal mine methane, and natural gas facilities. Alkane Energy has natural gas, coal bed methane, coal mine methane, and sh …
  • Matsuda Sangyo Co., Ltd. (7456):企業概要、財務及び戦略的SWOT分析
    Summary Matsuda Sangyo Co., Ltd. (Matsuda) is a precious metal and environment company. The company’s business lines include precious metals related business, environmental related business, and foodstuff related business. Its products include wiring connection materials, film forming materials, pre …
  • Romelectro S.A.:企業の戦略的SWOT分析
    Romelectro S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Tyrogenex Inc:企業のM&A・提携動向(医療分野)
    Summary Tyrogenex Inc (Tyrogenex) formerly Xcovery, Inc., is a biopharmaceutical company that develops next generation targeted therapeutics for cancer. The company develops dual vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitors for wet age-related ma …
  • The Warehouse Group Limited (WHS):企業財務及び戦略的SWOT分析
    The Warehouse Group Limited (WHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆